查看购物车
  • Traditional Chinese
  • English
2021-2031年北美治疗性疫苗市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871433

2021-2031年北美治疗性疫苗市场报告：范围、细分、动态和竞争分析

North America Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 121 Pages | 订单完成后即时交付

价格

预计北美治疗性疫苗市场将大幅成长，到 2031 年将达到约 1,360,744.52 千美元，高于 2024 年的 565,764.46 千美元，2024 年至 2031 年的年复合成长率(CAGR) 为 13.4%。

执行摘要和市场分析

北美治疗性疫苗市场主要分为三大区域：美国、加拿大和墨西哥。由于癌症发病率上升、研发投入增加以及新产品上市数量显着增长等因素，美国预计将成为市场成长的主要驱动力。此外，新产品上市、获得监管部门批准、建立合作伙伴关係和进行收购等策略措施也进一步推动了该地区治疗性疫苗市场的成长。

市场区隔分析

治疗性疫苗市场可以透过产品类型、技术和最终用户等多个细分市场进行分析。

  • 按产品划分：市场分为癌症疫苗、传染病疫苗和其他疫苗，其中癌症疫苗在 2024 年将占据最大的市场份额。
  • 按技术划分：市场分为同种异体疫苗和自体疫苗，预计到 2024 年，同种异体疫苗将占据市场份额的主导地位。
  • 按最终用户划分：最终用户包括医院、诊所等，其中医院在 2024 年将占最大份额。

市场展望

受人口老化、生活方式改变和环境影响等因素驱动，癌症、神经系统疾病和自体免疫疾病等慢性病在全球的发生率呈上升趋势。世界卫生组织（世卫组织）的数据显示，非传染性疾病每年导致4,100万人死亡，占总死亡人数的74%。 2022年，全球新增癌症病例约2,000万例，约970万人死于癌症。此外，2024年4月发表在《柳叶刀神经病学》杂誌上的一项研究表明，截至2021年，全球有超过30亿人（占全球人口的43%）患有神经系统疾病。自体免疫疾病影响已开发国家5%至10%的人口，约有5,000万美国人受到影响。世卫组织也报告称，截至2023年8月，全球有超过180万人患有多发性硬化症。

这些令人震惊的统计数据凸显了开发创新疗法的迫切需求。治疗性疫苗旨在治疗现有疾病而非预防疾病，目标是激活免疫系统以对抗特定疾病。例如，Sipuleucel-T（Provenge）疫苗已显示出提高前列腺癌患者存活率的潜力。随着对慢性病创新疗法的需求不断增长，治疗性疫苗有望为疾病的长期管理和改善患者预后提供新的途径。

国家概况

北美治疗性疫苗市场主要由美国、加拿大和墨西哥组成，其中美国在2024年将占据最大的市场份额。美国治疗性疫苗市场的成长主要受慢性疾病（包括癌症和传染病）日益普遍的推动。美国癌症协会报告称，2022年美国新增癌症病例超过190万例，导致约61万人死亡。预计到2024年，美国癌症确诊病例将达200万例。癌症病例的激增推动了对创新治疗方案的需求，而治疗性疫苗为传统疗法提供了极具前景的替代方案。 Provenge是首个获得FDA批准的前列腺癌治疗性疫苗，它充分展现了免疫疗法延长患者存活期的潜力。癌症发生率的上升促使人们加大研发投入，并促进企业与学术机构之间的合作。

公司简介

治疗性疫苗市场的主要参与者包括CureVac SE、THERAVECTYS SA、Transgene SA、INOVIO Pharmaceuticals Inc、ISA Pharmaceuticals BV、Amgen Inc、Merck & Co Inc、印度血清研究所、BioNTech SE和Dendreon等。这些公司正采取多种策略，包括扩张、产品创新以及併购，以增强其产品组合併扩大市场份额。

目录

第一章：引言

第二章：执行概要

  • 关键见解

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基数：
    • 数据三角测量：
    • 国家层面资料：

第四章：北美治疗性疫苗市场－主要市场动态

  • 市场驱动因素
    • 慢性病盛行率上升
    • 增加疫苗研发的投资与资金投入
  • 市场限制
    • 监管挑战
  • 市场机会
    • 拓展产品线
  • 未来趋势
    • 疫苗技术的进步
  • 驾驶员和安全带的影响：

第五章：治疗性疫苗市场－北美市场分析

  • 2021-2031年北美治疗性疫苗市场收入
  • 北美治疗性疫苗市场预测分析

第六章：北美治疗性疫苗市场分析－依产品分类

  • 癌症疫苗
  • 传染病疫苗
  • 其他的

第七章：北美治疗性疫苗市场分析－依技术划分

  • 同种异体疫苗
  • 自体疫苗

第八章：北美治疗性疫苗市场分析－以最终用户划分

  • 医院
  • 诊所
  • 其他的

第九章：北美治疗性疫苗市场—国别分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第十章：治疗性疫苗市场－产业概况

  • 概述
  • 治疗性疫苗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十一章：公司简介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第十二章：附录

Product Code: BMIRE00032090

The North America therapeutic vaccines market is projected to grow significantly, reaching approximately USD 1,360,744.52 thousand by 2031, up from USD 565,764.46 thousand in 2024, reflecting a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in North America is divided into three main regions: the United States, Canada, and Mexico. The U.S. is expected to be a key driver of market growth due to several factors, including the rising incidence of cancer, increased investment in research and development, and a notable rise in product launches. Additionally, strategic initiatives such as the introduction of new products, regulatory approvals, partnerships, and acquisitions are further enhancing the growth of the therapeutic vaccine market in this region.

Market Segmentation Analysis

The therapeutic vaccines market can be analyzed through various segments, including product type, technology, and end user.

  • By Product: The market is categorized into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
  • By Technology: The market is divided into allogenic and autologous vaccines, where allogenic vaccines are expected to dominate the market share in 2024.
  • By End User: The end-user segment includes hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The prevalence of chronic conditions such as cancer, neurological disorders, and autoimmune diseases is on the rise globally, driven by factors like aging populations, lifestyle changes, and environmental influences. According to the World Health Organization (WHO), noncommunicable diseases lead to 41 million deaths annually, representing 74% of total mortality. In 2022, around 20 million new cancer cases were diagnosed, with approximately 9.7 million deaths attributed to the disease. Furthermore, a study published in The Lancet Neurology in April 2024 indicated that over 3 billion people, or 43% of the global population, were living with neurological conditions as of 2021. Autoimmune diseases affect 5-10% of the population in industrialized nations, impacting around 50 million Americans. The WHO also reported that over 1.8 million people worldwide suffered from multiple sclerosis as of August 2023.

These alarming statistics underscore the urgent need for innovative therapeutic solutions. Therapeutic vaccines are designed to treat existing diseases rather than prevent them, aiming to activate the immune system to target specific diseases. For instance, the Sipuleucel-T (Provenge) vaccine has shown promise in improving survival rates for prostate cancer patients. As the demand for innovative treatments for chronic diseases rises, therapeutic vaccines are positioned to provide new avenues for long-term disease management and enhanced patient outcomes.

Country Insights

The North American therapeutic vaccines market is primarily composed of the U.S., Canada, and Mexico, with the U.S. holding the largest market share in 2024. The growth of the therapeutic vaccines market in the U.S. is fueled by the increasing prevalence of chronic diseases, including cancer and infectious diseases. The American Cancer Society reported that in 2022, over 1.9 million new cancer cases were diagnosed, resulting in approximately 610,000 deaths. In 2024, the number of cancer diagnoses in the U.S. is expected to reach 2 million. This surge in cancer cases is driving the demand for innovative treatment options, with therapeutic vaccines offering promising alternatives to traditional therapies. Provenge, the first FDA-approved therapeutic cancer vaccine for prostate cancer, exemplifies the potential of immunotherapies to extend patient survival. The rising incidence of cancer is prompting increased investment in research and development and fostering collaborations between companies and academic institutions.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon, among others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase their market presence.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. North America Therapeutic Vaccines Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic Conditions
    • 4.1.2 Increasing Investments and Funding for Vaccine Development
  • 4.2 Market Restraints
    • 4.2.1 Regulatory Challenges
  • 4.3 Market Opportunities
    • 4.3.1 Extending Product Pipeline
  • 4.4 Future Trends
    • 4.4.1 Advancements in Vaccine Technology
  • 4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - North America Market Analysis

  • 5.1 North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 5.2 North America Therapeutic Vaccines Market Forecast Analysis

6. North America Therapeutic Vaccines Market Analysis - by Product

  • 6.1 Cancer Vaccine
    • 6.1.1 Overview
    • 6.1.2 Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.2 Infectious Disease Vaccine
    • 6.2.1 Overview
    • 6.2.2 infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.3 Others
    • 6.3.1 Overview
    • 6.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. North America Therapeutic Vaccines Market Analysis - by Technology

  • 7.1 Allogenic Vaccine
    • 7.1.1 Overview
    • 7.1.2 Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Autologous Vaccine
    • 7.2.1 Overview
    • 7.2.2 Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. North America Therapeutic Vaccines Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. North America Therapeutic Vaccines Market - Country Analysis

  • 9.1 North America
    • 9.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.2.1 United States: North America Therapeutic Vaccines Market Share - by Product
        • 9.1.1.2.2 United States: North America Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.2.3 United States: North America Therapeutic Vaccines Market Share - by End User
      • 9.1.1.3 Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.3.1 Canada: North America Therapeutic Vaccines Market Share - by Product
        • 9.1.1.3.2 Canada: North America Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.3.3 Canada: North America Therapeutic Vaccines Market Share - by End User
      • 9.1.1.4 Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.4.1 Mexico: North America Therapeutic Vaccines Market Share - by Product
        • 9.1.1.4.2 Mexico: North America Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.4.3 Mexico: North America Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Therapeutic Vaccines Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Dendreon
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 BioNTech SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Serum Institute of India Pvt. Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Merck & Co Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Amgen Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 ISA Pharmaceuticals BV
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 INOVIO Pharmaceuticals Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Transgene SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 THERAVECTYS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CureVac SE
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. North America Therapeutic Vaccines Market Segmentation
  • Table 2. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 3. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
  • Table 4. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
  • Table 5. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 6. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 7. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 8. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 9. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 10. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 11. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 12. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 13. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 14. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 15. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 16. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 17. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 18. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. North America Therapeutic Vaccines Market Segmentation - Country
  • Figure 2. North America Therapeutic Vaccines Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. North America Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 6. Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. North America Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 10. Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. North America Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. North America Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 18. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 19. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 20. Growth Strategies in the Therapeutic Vaccines Market